Canadian clinical guidelines recommend pharmacological treatments for obesity, specifically GLP-1 receptor agonists such as liraglutide and semaglutide, in addition to behavioral and nutritional interventions for adults with a BMI of 30 kg/m2 or ≥27 kg/m2 with complications related to adiposity [37]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.